The Biotech Rollercoaster Ride: From Lab To Buyout

Caixa Capital Risc's Pablo Cironi On Sanifit's Story

30 Nov 2021

After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.

Spanish artist Joan Miró designed the Caixa logo • Source: Alamy

Having just seen portfolio company Sanifit Therapeutics S.A. snapped up by Vifor Pharma Group , constituting the largest acquisition in the Spanish biotech sector over the past few years, Pablo Cironi, director of life sciences investments at Caixa Capital Risc, has spoken to Scrip about the journey from seed funding to acquisition by a major pharma company.

On 22 November, Vifor revealed it was paying €205m upfront for Sanifit, founded as a spin-off of the University of the Balearic Islands

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

08 May 2025

• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

08 May 2025

• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

06 May 2025

• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

09 May 2025

• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.